恩瑞格（地拉罗司）是什么？

It is currently available in more than 80 countries; so, what is Enrego (deferasirox)?

Deferasirox is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron chelator approved by the U.S. FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. In Europe, it is recommended as a first-line drug for patients with thalassemia iron overload over 6 years old.

In 2010, Enrige dispersible tablets were approved for marketing in China and are approved for the treatment of chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients aged 2 years and above, and for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above.

Thalassemia is a rare genetic disease. In addition to iron elimination and blood transfusion, most patients in China use oral deferasirox dispersible tablets for treatment.

Enrig's taboos:

1. It is prohibited for those who are known to be allergic to the active ingredients or any excipients.

2. It should not be used in combination with other iron chelation treatments because the safety of such combined use has not been established.

3. It is prohibited to be used in patients with creatinine clearance <40mL/min or serum creatinine >2 times the upper limit of normal for the corresponding age; patients with poor general condition, high-risk myelodysplastic syndrome (MDS) or advanced malignant tumors; patients with platelet count <50x109/L.

Drug interactions with Enrego:

1. Avoid combination with strong inducers of UDP-glucuronosyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors) and cholestyramine.

2. It cannot be administered at the same time as aluminum-containing antacids. Not to be combined with other iron chelation treatments.

3. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Withhold Enrig at least 5 days before performing Gallium-67 imaging.